



Pharmacology

Subject : *Pharmacology*

Lec no : *Lecture " 8 "*

Done By : *Zeyad tareq*

وقار زرنى علنا

تجدون في guidance مادة الفارما على موقع النادي :



للوصول الى guidance الفارما و تفاريغ المادة كاملة :



كل اعمال الفريق العلمي تنشر على قناة التيليجرام



PHARMACODYNAMICS

Types of Drug Action:

- **Local or topical action:** drugs act on site of application e.g. ointment or eye drops.
- **Systemic or general action:** the drug acts after administration and distribution by circulation to various tissues. e.g. Aspirin
- **Reflex or remote action:** the drug acts locally at one site to produce reflex action elsewhere. e.g. Ammonia inhalation → irritation of nose → reflex stimulation of respiration

Mechanism (Mode) of Action of Drugs

- Drugs can induce a tissue response, initially through:
 - Body control systems (the regulatory proteins):** involving interactions with:
 - (1) Receptors
 - (2) Ion channels
 - (3) Enzymes
 - (4) Carrier molecules
 - Other mechanisms:**
 - (5) Subcellular structures
 - (6) Genetic apparatus *Act on DNA*
 - (7) Physical mechanisms
 - (8) Chemical mechanisms

Any molecule
bind with the receptor
is ligand

1) Receptor-Mediated Mechanisms


- **Receptors** are specific cellular macromolecules (usually proteins) that interact with a ligand (**binding**) to produce a response.
- **Ligand:** any molecule that can combine with the receptor. A ligand that activates receptor is called agonist. A ligand that blocks the receptor is called antagonist

هون ligand هي اي molecule ممكن يربط بالreseptor وممكن يكون agonist او antagonist

Agonist: ligand that activates the receptor
Antagonist: ligand that blocks the receptor

1. Ligand-gated ion channels: (for fast neurotransmitters)

- Receptors are **ion-selective channels** in the plasma membrane.
 - Binding of agonist to the extracellular part of receptor → opening of the channel → alteration in membrane potential or change in intracellular ion concentration → change in cell activity,
 - e.g. **GABA_A receptors (Cl⁻ channels)**.



هالن reseptor بكون من جزاين 1 extracellular part 2 intracellular part
ربط في ligand

لما يربط ligand بال extracellular part بعمل تغير بال intracellular part

يؤدي إلى فتح ودخول الأيونات

مثال GABA_A receptors


هناك reseptors ترتبط فيها GABA_A neurotransmitter وتؤدي إلى

دخول أيونات الكلور إلى داخل الخلية وتعمل Hyperpolarization

وبالتالي تعمل inhibition of action potential

2. G protein-Coupled Receptors (for slow neurotransmitters)

- Receptor consists of 7 transmembrane subunits which are linked to G proteins.
- The G protein is a trimer (α , β and γ).
- Agonist binding \rightarrow dissociation of α subunit which regulates activity of several effectors.



هوں فیہ G-protein complex بتکون من 3 subunits
Alpha α 1
beta β 2
gamma γ 3

لما يرتبط ligand بال receptor يؤدي إلى فتح α subunit

وتحول ATP \rightarrow CAMP با enzyme adenylyl cyclase وتحويل

وتؤدي إلى سلسلة تفاعلات داخل الخلية.


Types of G Proteins

- G_s (stimulatory)** \rightarrow increased cAMP \rightarrow activation of specific proteins.
 - G_i (inhibitory)** \rightarrow decreased cAMP \rightarrow inhibition of specific proteins.
 - G_q (query)** \rightarrow increased DAG (diacylglycerol) and IP₃ (inositol triphosphate) \rightarrow increased intracellular Ca⁺⁺ and activate PKC (protein kinase C)
- Examples: β -adrenergic receptors linked to G_s protein
 α_2 - adrenergic receptors linked to G_i protein
 α_1 - adrenergic receptors linked to G_q protein


3. Receptors linked to Tyrosine Kinase (RTKs)

- The receptor is formed of two domains:
 - An extracellular domain, to which the agonist binds.
 - An intracellular domain, which is a tyrosine kinase enzyme (effector).
 - A transmembrane segment connecting two domains.

- e.g. insulin receptors




Agonist binds with it \leftarrow extracellular domains - هافن اذ Receptor بكونه من جزأين
 consist of Tyrosine Kinase \leftarrow intracellular domain (2



طريقة العمل :-

هو بكونا 2 monomers منفصلين عن بعض
 لما يربط agonist بال receptor بقربوا على



بعض ويربطوا مع بعض بعضين بعملوا activate

لبروتين ويغير Cellular response.

مثال عليه - هرمون الأنسولين

4. Intracellular (DNA-linked) receptors (very slow)


- The ligand enter the target cell and combine with intracellular receptor proteins → complex → acts on nuclear DNA → modify transcription of the nearby gene → modify protein production → changes in the structure or function of the target tissue.
- Examples: receptors for **corticosteroids**, **sex hormones**, **thyroid hormones** and **vitamin D**

هون يكون ال Receptor داخل الخلية عكس اللي اخذناهم فوه
الي كان فيهم ال Receptor على سطح الخلية.

طريقة العمل: يدخل ligand من cell membrane (عشانه فيل ligand يكون
lipophilic)

ويرتبط بال Receptor ويغير Cellular response والي هو DNA تغيير في
ويؤدي إلى صناعة بروتين جديد يغير في وظائف الخلية.

* هامن النوع من ال Receptors بطول ليغير في response بسبب تغيير DNA



5. Nitric Oxide (NO) Receptors:

- NO receptors are protein receptors inside the cell. Binding of NO receptors → formation of a "second messenger" within the cell.
- The most common: NO activates guanylyl cyclase enzyme → cyclic GMP (cGMP).
- NO receptors are activated by many drugs that increase NO level e.g. nitroglycerine.

هو Nitric Oxide is ligand ويؤثر داخل الخلية


ويجعل على مبدأ Second messenger

مثال دواء nitroglycerine يعطى لمرضى الذبحة الصدرية

بجعل Vasodilation فيتغير كمية الدم الجار بالشرايين فيترجج الجهد

الذي يبذل القلب لضخ الدم للأعضاء.

Biological response to drug-receptor binding:



- **Affinity**: ability of drug to bind with the receptor to form D/R complex
- **Efficacy**: ability of D/R complex to evoke a response.
- **K_a** is the association constant
- **K_d** is the dissociation constant

انارة
معدل ربط الدواء وفكوا
من reseptor

* هسا لما الدواء يربط بال receptor با إما يكون :-

1. Agonist effect: → Activates receptor

- Agonist has **1. Affinity** **2. High Efficacy** **3. Rapid rate of ass. & diss.**
- Theories for drug-receptor interaction: **receptors** هاي نظريات ربط الدواء مع ال

1. Receptor occupation theory: response (efficacy) depends on **number of occupied receptors** receptors ال يعتمد على عدد ال
 اول نظرية انو تاثير الدواء يعتمد على عدد ال receptors التي ربط معهم

* - **When maximum effect is reached, still some receptors remain free**

(spare receptors) → receptors انو لما الدواء يوصل لاقصى تاثير يكون لسا فيه **spare receptors** فاضية اسمها

2. Rate theory: response (efficacy) depends on rate of association (**K_a**) and rate of dissociation (**K_d**)
 ثاني نظرية تحكي انو تاثير الدواء يعتمد على سرعة ربط وفك الدواء من ال reseptore

* • **Response will never exceed a certain limit** whatever the drug concentration. This is termed **E_{max}** i.e. **the maximal response or effect**

• e.g. - **acetylcholine (Ach) activates nicotinic receptors → skeletal muscle contraction.**


- **adrenaline activates beta adrenoceptors → increased HR**

• **They are 2 types of drug responses:**

1. Graded dose-response: the response increases by increasing the agonist

e.g. increases of heart rate against different doses of adrenaline.


اول نوع من response of drugs انو كل ما نزيد الجرعة بزيد تاثير الدواء لكن هاض الحكي مش مستمر بوقف عند حد معين عندو قد ما نزيد الجرعة ما رح يزيد تاثير الدواء اقصى تاثير للدواء اسمو Emax



potency
 The dose that cause 50% response

2. Quantal dose-response : the response is all or none e.g. the % of epileptic patients who are treated by different doses of an antiepileptic drug

ثاني نوع يعتمد على نسبة الاشخاص التي تعالجوا من الدواء عند جرعة معينة يعني لما احكيك انو عند الجرعة 5gm يكون تاثير الدواء 5% هاي النسبة معناها انو 5% من الاشخاص عند هاي الجرعة كان للدواء تاثير عليهم وتعالجو



هاي معناها مش انو الدواء ما الو response
 معناها انو الدواء بربط بالreseptor ويمنع الادوية الثانية
 انها تاثر على الreseptor وبالتالي تثبيط باقي الادوية

2. Antagonist effect:



- Antagonist has: 1. **Affinity** 2. **No Efficacy** 3. **Slow Rate of ass. & diss.**

- **Types of receptor (pharmacological) antagonists:**

1- Competitive Antagonist	2- Noncompetitive Antagonist
<ul style="list-style-type: none"> • Antagonist competes with the agonist for the same recognition site of the receptor. 	<ul style="list-style-type: none"> • Antagonist binds irreversibly with recognition site of the receptor or to an allosteric site (a site away from <u>recognition site</u>) to prevent binding of agonist with receptor or prevent activation of receptor by agonist
<ul style="list-style-type: none"> • Duration of antagonism depends on the relative plasma concentrations of agonist and antagonist. • Antagonist can be Displaced by excess agonist (surmountable) 	<ul style="list-style-type: none"> • Duration of antagonism depends on synthesis of new receptors • Antagonist can Not be Displaced by agonist (non-surmountable)
<ul style="list-style-type: none"> • Causes parallel shift to the right in the log dose-response curve i.e. No change in E_{max} but $\downarrow\downarrow$ in potency ($\uparrow\uparrow$ in ED_{50}) 	<ul style="list-style-type: none"> • Causes downward shift in the log dose-response curve with $\downarrow\downarrow$ in E_{max}, but No change in potency (ED_{50})
<ul style="list-style-type: none"> • Examples: Atropine (muscarinic blocker) 	<ul style="list-style-type: none"> • Example: Phenoxybenzamine (α - blocker)

Competitive Antagonist:-

* Here Antagonist competes with agonist

يعني ال Antagonist يكون نفس التركيب
الكيميائي لل Agonist فيصير يناافسوا
على مكان الربط ويربطه محلو ويمنعوا
من الربط على receptor

for same site of binding on receptor

* To unbind antagonist from receptor you


can increase the dosage of drug, the

drug will replace the antagonist

* Here there is no change in E_{max}

, but Potency will be increased.

↳ The dosage need to reach
50% of response of drug (ED_{50})



There is increasing in potency when we added antagonism.